Presence of tumor DNA in plasma of breast cancer patients: Clinicopathological correlations

Cancer Research

Volumn 59, Issue 13, 1999, Pages 3251-3256

  Silva, Jose M ^a   Dominguez, Gemma ^a   Garcia, Jose M ^a   Gonzalez, Rocio ^a   Villanueva, Maria J ^a   Navarro, Fatima ^a   Provencio, Mariano ^a   Martin, Santiago San ^b   España, Pilar ^a   Bonilla, Felix ^a,c  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b HOSPITAL UNIVERSITARIO SANTA CRISTINA   (Spain)

^c Molecular Diagnostic Unit   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD LEVEL; BREAST CANCER; CANCER GRADING; CANCER GROWTH; CANCER INVASION; DISEASE MARKER; DISEASE SEVERITY; DNA DETERMINATION; FEMALE; GENE MUTATION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN METHYLATION;

EID: 0033168068     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Kelsey, J. L., and Horm-Ross, P. L. Breast cancer: magnitude of the problem and descriptive epidemiology. Epidemiol. Rev., 15: 7-16, 1993.
2. Veronesi, U., Goldhirsch, A., and Yarnold, J. Breast cancer. In: M. Peckham, H. M. Pinedo, and U. Veronesi (eds.), Oxford Textbook of Oncology, Vol. 2, pp. 1243-1289. New York, NY: Oxford University Press, 1995.
3. Lopez-Abente, G., Pollán, M., Escolar, A., Errezola, M., and Abraira, V. Atlas of Cancer Mortality and Other Causes of Death in Spain, 1978-1992. Madrid: Fundación Científica de la Asociación Española contra el Cáncer, 1996.
4. Mao, L., Hruban, R. H., Boyle, J. O., Tockman, M., and Sidransky, D. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res., 54: 1634-1637, 1994.
5. Sidransky, D., Von Eschenbach, A., Tsai, Y. C., Jones, P., Summerhayes, I., Marshall, F., Paul, M., Green, P., Hamilton, S. R., Frost, P., and Vogelstein, B. Identification of p53 gene mutations in bladder cancers and urine samples. Science (Washington DC), 252: 706-709, 1991.
6. Kondo, H., Sugano, K., Fukamaya, N., Kyogoku, A., Nose, H., Shimada, K., Ohkura, H., Ohtsu, A., Yishida, S., and Shimosato, Y. Detection of point mutations in the K-ras oncogene at codon 12 in pure pancreatic juice for diagnosis of pancreatic carcinoma. Cancer (Phila.), 73: 1589-1594, 1994.
7. Sidransky, D., Tokino, T., Hamilton, S. R., Kinzler, K. W., Levin, B., Frost, P., and Vogelstein, B. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science (Washington DC), 256: 102-105, 1992.
8. Motomura, K., Koyama, H., Noguchi, S., Inaji, H., and Azuma, C. Detection of c-erbB-2 gene amplification in nipple discharge by means of polymerase chain reaction. Breast Cancer Res. Treat., 33: 89-92, 1995.
9. Shapiro, B., Chakrabarly, M., Cohn, E. M., and Leon, S. A. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer (Phila.), 51: 2116-2120, 1983.
10. Leon, S. A., Shapiro, B., Sklaroff, D. M., and Yaros, J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res., 37: 646-650, 1977.
11. Koffler, D., Agnello, V., Winchester, R., and Kunkel, H. G. The occurrence of single-stranded DNA in the serum of patients with SLE and other diseases. J. Clin. Investig., 52: 198-204, 1973.
12. Stroun, M., Anker, P., Maurice, P., Lyautey, J., Lederrey, C., and Beljanski, M. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology, 46: 318-322, 1989.
13. Lo, Y. M. D., Corbetta, N., Chamberlain, P. F., Rai, V., Sragent, I. L., Redman, C. W. G., and Wainscoat, J. S. Presence of fetal DNA in maternal plasma and serum. Lancet, 350: 485-487, 1997.
14. Lo, Y. M., Tein, M. S., Lau, T. K., Haines, C. J., Leung, T. N., Poon, P. M., Wainscoat, J. S., Johnson, P. J., Chang, A. M., and Hjelm, N. M. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am. J. Hum. Genet., 62: 768-775, 1998.
15. Lo, Y. M. D., Hjelm, N. M., Fidler, C., Sargent, I. L., Murphy, M. F., Chamberlain, P. F., Poon, P. M. K., Redman, C. W. G., and Wainscoat, J. S. Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. N. Engl. J. Med., 339: 1734-1738, 1998.
16. Lo, Y. M. D., Tein, M. S. C., Pang, C. C. P., Yeung, C. K., Tong, K-L., and Hjelm, N. M. Presence of donor-specific DNA in plasma of kidney and liver-transplant recipients. Lancet, 351: 1329-1330, 1998.
17. Mulcahy, H. E., Lyautey, J., Lederrey, C., Cheng, X. Q., Anker, P., Alstead, E. M., Ballinger, A., Farthing, M. J., and Stroun, M. A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin. Cancer Res., 4: 271-275, 1998.
18. Sorenson, G. D., Pribish, D. M., Valone, F. H., Memoli, V. A., Bzik, D. J., and Yao, S. L. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol. Biomark. Prev., 3: 67-71, 1994.
19. Anker, P., Lefort, F., Vasioukhin, V., Lyautey, J., Lederrey, C., Cheng, X. Q., Stroun, M., Mulcahy, H. E., and Farthing, J. G. K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer. Gastroenterology, 112: 1114-1120, 1997.
20. Hibi, K., Robinson, C. R., Booker, S., Wu, L., Hamilton, S. R., Sidransky, D., and Jen, J. Molecular detection of genetic alterations in serum of colorectal cancer patients. Cancer Res., 18: 1405-1407, 1998.
21. Kopreski, M. S., Benko, F. A., Kwee, C., Leitzel, K. E., Eskander, E., Lipton, A., and Gocke, C. D. Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer. Br. J. Cancer, 76: 1293-1299, 1997.
22. Vasioukhin, V., Anker, P., Maurice, P., Lyautey, J., Lederrey, C., and Stroun, M. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br. J. Haematol., 86: 774-779, 1994.
23. Chen, X. Q., Stroun, M., Magnenat, J. L., Nicod, N. P., Kurt, A-M., Lyautey, J., Lederrey, C., and Anker, P. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat. Med., 2: 1033-1035, 1996.
24. Silva, J. M., Gonzalez, R., Dominguez, G., Garcia, J. M., España, P., and Bonilla, F. TP53 gene mutations in plasma DNA of cancer patients. Genes Chromosomes Cancer, 24: 160-161, 1999.
25. Sánchez.-Cespedes, M., Monzó, M., Resell, R., Pifarré, A., Calvo, R., Lopez-Cabrerizo, M. P., and Astudillo, J. Detection of chromosome 3p alterations in serum DNA of non-small-cell lung cancer patients. Ann. Oncol., 9: 113-116, 1998.
26. Esteller, M., Sanchez-Cespedes, M., Rosell, R., Sidransky, D., Baylin, S. B., and Herman, J. G. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res., 59: 67-70, 1999.
27. Nawroz, H., Koch, W., Anker, P., Stroun, M., and Sidransky, D. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat. Med., 2: 1035-1037, 1996.
28. Goessl, C., Heicapell, R., Münker, R., Anker, P., Stroun, M., Krause, H., Müller, M., and Miller, K. Microsatellite analysis of plasma DNA from patients with clear cell renal carcinoma. Cancer Res., 58: 4728-4732, 1998.
29. Wong, I. H. N., Lo, Y. M. D., Zhang, J., Liew, C-T., Ng, M. H. L., Wong, N., Lai, P. B. S., Lau, W. Y., Hjelm, N. M., and Johnson, P. J. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res., 59: 71-73, 1999.
30. Theillet, C., Lidereau, R., Escot, C., Hutzell, P., Brunet, M., Gest, J., Schlom, J., and Callahan, R. Loss of a c-H-ras-1 allele and aggressive human primary breast carcinomas. Cancer Res., 46: 4776-4781, 1986.
31. Mangues, R., Kahn, J. M., Seidman, I., and Pellicer, A. An overexpressed N-ras proto-oncogene cooperates with N-methylnitrosourea in mouse mammary carcinogenesis. Cancer Res., 54: 6395-6401, 1994.
32. Kumar, R., Sukumar, S., and Barbacid, M. Activation of ras oncogenes preceding the onset of neoplasia. Science (Washington DC), 248: 1101-1104, 1990.
33. Crook, T., Crossland, S., Crompton, M. R., Osin, P., and Gusterson, B. A. p53 mutations in BRCA1-associated familial breast cancer. Lancet, 350: 638-639, 1997.
34. Sjögren, S., Inganäs, M., Norberg, T., Lindgren, A., Nordgren, H., Holmberg, L., and Bergh, J. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J. Natl. Cancer Inst., 88: 173-182, 1996.
35. Hollstein, M. Sidransky, D., Vogelstein, B., and Harris, C. C.p53 mutations in human cancers. Science (Washington DC), 253: 49-53, 1991.
36. Gretarsdottir, S., Thorlacius, S., Valgardsdottir, R., Gudlaugsdottir, S., Sigurdsson, S., Steinarsdottir, M., Jonasson, J. G., Anamthawat-Jonsson, K., and Eyfjörd, J. E. BRCA2 and p53 mutations in primary breast cancer in relation to genetic instability. Cancer Res., 58: 859-862, 1998.
37. Patel, U., Grundfest-Broniatowski, S., Gupta, M., and Banerjee, S. Microsatellite instabilities at five chromosomes in primary breast tumors. Oncogene, 9: 3695-3700, 1994.
38. Toyama, T., Iwase, M., Yamashita, H., Iwata, H., Yamashita, T., Ito, K., Hara, Y., Suchi, M., Kato, T., Nakamura, T., and Kobayashi, S. Microsatellite instability in sporadic human breast cancer. Int. J. Cancer, 68: 447-451, 1996.
39. Phelan, C. M., Borg, A., Cuny, M., Crichon, C. N., Baldersson, T., Andersen, T. I., Caligo, M. A., Lidereau, R., Lindblom, A., Seitz, S., Kelsell, D., Hamann, U., Rio, P., Thorlacius, S., Papp, J., Olah, E., Ponder, B., Bignon, Y-J., Scherneck, S., Barkardottir, R., Borresen-Dale, A-L., Eyfjörd, J., Theillet, C., Thompson, A. M., Devilee, P., and Larsson, C. Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 target subregions associated with family history and clinical parameters. Cancer Res., 58: 1004-1012, 1998.
40. Hamann, U., Herbold, C., Costa, S., Solomayer, E-F., Kaufmann, M., Bastert, G., Ulmer, H. U., Frenzel, H., and Komitowski, D. Allelic imbalance on chromosome 13q: evidence for the involvement of BRCA2 and RB1 in sporadic breast cancer. Cancer Res., 56: 1988-1990, 1996.
41. Noviello, C., Courjal, F., and Theillet, C. Loss of heterozygosity on the long arm of chromosome 6 in breast cancer: possibly four regions of deletions. Clin. Cancer Res., 2: 1601-1606, 1996.
42. Deng, G., Lu, Y., Zlotnikov, G., Thor, A. N., and Smith, H. S. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science (Washington DC), 274: 2057-2059, 1996.
43. Anderson, L. A., Friedman, L., Osborne-Lawrence, S., Lynch, E., Weissenbach, J., Bowcock, A., and King, M-C. High-density genetic map of the BRCAI region of chromosome 17q12-q21. Genomics, 17: 618-623, 1993.
44. Steiner, G., Schoenberg, M. P., Linn, J. F., Mao, L., and Sidransky, D. Detection of bladder cancer recurrence by microsatellite analysis of urine. Nat. Med., 3: 621-624, 1997.
45. Skirnisdottir, S., Eiriksdottir, G., Baldersson, T., Barkardottir, R. B., Egilsson, V., and Ingvarsson, S. High frequency of allelic imbalance at chromosome region 16q22-23 in human breast cancer: correlation with high PgR and low S phase. Int. J. Cancer, 64: 112-116, 1995.
46. Brenner, A. J., and Aldaz, C. M. Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells. Cancer Res., 55: 2892-2895, 1995.
47. Oto, M., Miyake, S., and Yuasa, Y. Optimization of nonradioisotopic single strand conformation polymorphism analysis with a conventional minislab gel electrophoresis apparatus. Anal. Biochem., 213: 19-22, 1993.
48. Orita, M., Suzuki, Y., Sekiya, T., and Hayashi, K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics, 5: 874-879, 1989.
49. Singer-Sam, J., Yang, T. P., Mori, N., Tanguay, R. L., Le-Bon, J. M., Flores, C. J., and Riggs, A. D. DNA methylation in the 5′ region of the mouse PGK-I gene and a quantitative PCR assay for methylation. In: G. A. Clawson, D. B. Willis, A. Weissbach, and P. A. Jones (eds.), Nucleic Acid Methylation, Vol. 128, pp. 285-289. New York: Alan Bliss, Inc., 1990.
50. Armitage, P., and Berry, G. Statistical Methods in Medical Research. Oxford: Blackwell Scientific Publications, 1987.
51. Norberg, T., Lennerstrand, J., Inganäs, M., and Bergh, J. Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors. Int. J. Cancer, 79: 376-383, 1998.
52. Blaszyk, H., Hartmann, A., Tamura, Y., Saitoh, S., Cunningham, J. M., Mcgovern, R. M., Schroeder, J. J., Schaid, D. J., Ii, K., Monden, Y., Morimoto, T., Komaki, K., Sasa, M., Hirata, K., Okazaki, M., Kovach, J. S., and Sommer, S. S. Molecular epidemiology of breast cancer in northern and southern Japan: the frequency, clustering, and patterns of p53 gene mutations differ among these two low-risk populations. Oncogene, 13: 2159-2166, 1996.
53. Herman, J. G., Merlo, A., Mao, L., Lapidus, R. G., Issa, J-PJ., Davidson, N. E., Sidransky, D., and Baylin, S. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res., 55: 4525-4530, 1995.
54. O'Connell, P., Pekkel, V., Fuqua, S. A. W., Osborne, C. K., Clark, G. M., and Allred, D. C. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J. Natl. Cancer Inst., 90: 697-703, 1998.
55. Caponigro, F. CA 15.3 in human breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA). Int. J. Biol. Markers, 5: 73-76, 1990.
56. Castells, A., Puig, P., Mora, J., Boadas, J., Boix, L., Urgell, E., Solé, M., Capellá, G., Lluis, F., Fernandez-Cruz, L., Navarro, S., and Farré A. K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. J. Clin. Oncol., 17: 578-584, 1999.